Jin Zi-Bing, Okamoto Satoshi, Mandai Michiko, Takahashi Masayo
Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Chuo-ku, Kobe, Japan.
J Genet. 2009 Dec;88(4):417-24. doi: 10.1007/s12041-009-0063-5.
Retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, are the prodominant causes of human blindness in the world; however, these diseases are difficult to treat. Currently, knowledge on the mechanisms of these diseases is still very limited and no radical drugs are available. Induced pluripotent stem (iPS) cells are an innovative technology that turns somatic cells into embryonic stem (ES)-like cells with pluripotent potential via the exogenous expression of several key genes. It can be used as an unlimited source for cell differentiation or tissue engineering, either of which is a promising therapy for human degenerative diseases. Induced pluripotent cells are both an unlimited source for retinal regeneration and an expectant tool for pharmaprojects and developmental or disease modelling. In this review, we try to summarize the advancement of iPS-based technologies and the potential utility for retinal degenerative diseases. We also discuss the challenges of using this technology in the retinology field.
视网膜退行性疾病，包括年龄相关性黄斑变性和视网膜色素变性，是全球人类失明的主要原因；然而，这些疾病难以治疗。目前，关于这些疾病机制的知识仍然非常有限，且尚无根治药物。诱导多能干细胞（iPS细胞）是一项创新技术，通过外源表达几个关键基因，将体细胞转化为具有多能潜力的胚胎干细胞（ES细胞）样细胞。它可作为细胞分化或组织工程的无限来源，二者均是治疗人类退行性疾病的有前景的疗法。诱导多能细胞既是视网膜再生的无限来源，也是药物研发项目以及发育或疾病建模的理想工具。在本综述中，我们试图总结基于iPS细胞的技术进展及其对视网膜退行性疾病的潜在应用价值。我们还讨论了在视网膜病领域使用该技术所面临的挑战。
